Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.

ABSTRACT:

Purpose

HR+/HER2- aromatase inhibitor-resistant metastatic breast cancer can be treated with everolimus and a second AI until the cancer recurs. Targeting these everolimus-resistant patients with the latest standard of care, CDK4/6 inhibitors, has not been clearly addressed. Understanding the signaling transduction pathways, which everolimus resistance activates, will elucidate the mechanisms and offer treatment strategies of everolimus resistance.

Methods

To mimic the clinical setting, letrozole-resistant cells were used to generate an everolimus-resistant model (RAD-R). Reverse phase protein array (RPPA) was performed to reveal changes in the signaling transduction pathways, and expression levels of key proteins were analyzed. Inhibitors targeting the major signaling pathw

SUBMITTER: Petrossian K 

PROVIDER: S-EPMC6026053 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature